98%
921
2 minutes
20
Purpose: This study investigated the long-term progression of oscillatory potential (OP) implicit times (ITs) in individuals with preclinical diabetic retinopathy (DR) with and without levodopa (L-DOPA) treatment by quantifying functional and structural retinal changes.
Methods: Participants from the Motz et al. (2020) study were re-evaluated after 5 years, including individuals with diabetes mellitus (DM) who received L-DOPA treatment for 2 weeks (the DM + L-DOPA group; n = 14), those who did not (the DM group; n = 6), and non-diabetic healthy controls (the control group; n = 37). Retinal function and structure were assessed using dim-flash electroretinography (ERG) and optical coherence tomography (OCT).
Results: After 5 years, OP 1 and OP 2 ITs showed no significant differences among the groups (P > 0.05). The DM + L-DOPA OP IT values remained improved compared to baseline. The outer region thickness of the outer plexus layer (OPL) and ganglion cell layer (GCL) were significantly thinner in the DM + L-DOPA group compared to the DM group (P < 0.05). The DM group showed strong correlations between OP IT and OCT thickness across all retinal regions, whereas the DM + L-DOPA group correlations were similar to the control group.
Conclusions: Short-term L-DOPA treatment led to significant functional improvements after 2 weeks, with trends suggesting sustained benefit over 5 years. Inner retinal structural differences suggest potential long-term benefit of L-DOPA on retinal health. These findings support OP IT delays as early biomarkers for preclinical DR and suggest L-DOPA may provide lasting neuroprotective benefits.
Translational Relevance: Retinal dysfunction and inner retinal structural changes could be potential biomarkers for preclinical DR, and L-DOPA treatment may provide sustained benefits for the diabetic retina.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410260 | PMC |
http://dx.doi.org/10.1167/tvst.14.9.5 | DOI Listing |
CNS Neurol Disord Drug Targets
September 2025
College of Pharmacy, National University of Science and Technology, Muscat, Oman.
Neurological disorders are complex conditions characterized by impairment of the nervous system, affecting motor, cognitive, and sensory functions. Current treatments meet substantial obstacles, primarily due to the difficulty of transporting drugs across the blood-brain barrier and ineffective therapy for nerve regeneration. Emerging technologies, such as electrospinning, offer innovative solutions to overcome these challenges.
View Article and Find Full Text PDFActa Neurol Belg
September 2025
Department of Neurology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
Objective: This study aimed to retrospectively evaluate the prevalence of COVID-19 infection among patients with Parkinson's disease (PD), along with the clinical course and factors associated with mortality.
Methods: A total of 1,786 patients diagnosed with Parkinson's disease and registered at our hospital were screened. Among these, 222 had undergone PCR testing for COVID-19, of whom 76 tested negative and 152 tested positive, indicating a COVID-19 prevalence of 8.
Psychogeriatrics
September 2025
Clinical Neurosciences and Mental Health Department, Faculty of Medicine of Porto University, Porto, Portugal.
The dopaminergic system may be at the base of some neurobehavioral symptoms, as apathy and depression, and extrapyramidal symptoms, often seen in Alzheimer's disease patients. It can also have an impact on cognitive decline, as extrapyramidal symptoms, classically linked with dopamine dysfunction, are associated with increased risk of cognitive impairment and Alzheimer's disease progression. We review the knowledge of the dopaminergic system, emphasizing changes in Alzheimer's disease.
View Article and Find Full Text PDFEur J Neurol
September 2025
Department of Neuroscience 'Rita Levi Montalcini', University of Torino, Torino, Italy.
Background: The factors contributing to a poor response to subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD) are not yet fully understood. Accordingly, predicting the outcome might be challenging particularly in those who display an optimal response to the Levodopa challenge test.
Objective: To determine which factors may contribute to poor outcome of STN-DBS in PD.
Clin Auton Res
September 2025
Department of Neurology, University of Arkansas for Medical Sciences, 4301 W. Markham St., #500, Little Rock, AR, 72205-7199, USA.
Purpose: Orthostatic hypotension (OH) is a non-motor feature in people with Parkinson's disease that can lead to falls from syncope. Current knowledge is lacking on the effects of OH on gait function.
Methods: Participants enrolled in a prospectively monitored longitudinal cohort who had OH on vitals at one of two consecutive visits approximately 6 months apart were analyzed.